2017 papers internacionales. · 1. osteoporosis international = 262 2. j bone mineral research =...

2017Papers Internacionales.

Dr. Pedro Paulo Marín Larraín

Profesor Titular

Depto. Medicina Interna-Geriatría

Facultad de Medicina PUC

Director SCHOMM

Búsqueda en la web 2017.--.-..-

Google = 3.330.000 citas

Google Académico = 4.850 En español = 189

Pub Med “BONE” en 100 años.

2000

Osteoporosis 2017 = 1.832 papers

Web of Sciences – 2017.

Osteoporosis = 1.290 citas

• Terapias = 427

• Revisiones = 116

• Diagnóstico = 189

• Editoriales = 30–Resto abstracts, etc.

http://bibliotecas.uc.cl/

Web of Sciences - Revistas


1. Osteoporosis International = 262

2. J Bone Mineral Research = 104

3. Annals Rheumatic Disease = 55

4. Archives of Osteoporosis = 40

5. Arthritis Rheumatology = 24

6. Bone = 20

7. Annals of Internal Medicine = 17

Medicine= 16, Rheumatology= 14, JAGS = 10 Maturitas=7

• USA = 281

• China = 211

• Japón = 93

• UK = 85

• Brasil = 30

• Argentina = 12

• México = 10

• Colombia = 2

Web of Sciences- Países.

ESCRITOS en ESPAÑOL = 5


Web of Sciences - ACP.

• Treatment of Low Bone Density or Osteoporosis to Prevent Fractures in Men and Women: A Clinical Practice Guideline Update From the American College of Physicians.

Amir Qaseem, MD, PhD, MHA; Mary Ann Forciea, MD; Robert M. McLean, MD; and Thomas D. Denberg, MD, PhD; for the Clinical

Guidelines Committee of the American College of Physicians*

Ann Intern Med. 2017;166:818-839

28 VECES CITADO EN EL AÑO 2017

UK clinical guideline for the prevention and treatment of osteoporosis.

The National Osteoporosis Guideline Group (NOGG)

Arch Osteopor (2017) 12: 43This article is an open access publication

CITADO 12 VECES

Decreasing trend of hip fractures incidence in Italy between 2007and 2014: epidemiological changes due to population aging

Archives of Osteoporosis (2018) 13:23

Hospitalizaciones anuales por fracturas de caderas

Decreasing trend of hip fractures incidence in Italybetween 2007 and 2014:

epidemiological changes due to population aging.


SUBEN Hospitalizaciones por fracturas de caderas >85 AÑOS.

HOMBRES

Decreasing trend of hip fractures incidence in Italy between 2007and 2014: epidemiological changes due to population aging.


Hospitalizaciones anuales por fracturas de caderas

Rapid Geriatric Assessment

of Hip Fracture.

Jesse Zanker, MBBS, Gustavo Duque, MD

Review: Pharmacological treatment of osteoporosis in the oldest old.

• -.-.-.the fact that evidence of the antifractureefficacy of osteoporosis treatments comes mainly from randomized controlled trials in postmenopausal women with a mean age of 70–75 years.

• This review discusses the pharmacological management of osteoporosis in the oldest old (>80 years).-.-.there is currently sufficient evidence to initiate appropriate treatment in the elderly with osteoporosis and osteoporotic fractures.

Clinical Interventions in Aging 2017:12 1065–1077

10 years Denosumab treatment in postmenopauseal women with

osteoporosis: results from the phase 3 randomized

FREEDOM trial and open label extension.

Lancet Diabetes Endocrinology 2017, 5 (7):513-523

CITADO 24 VECES

Vertebral Fractures After Discontinuation ofDenosumab: A Post Hoc Analysis of the Randomized

Placebo-Controlled FREEDOM Trial and Its Extension.

Journal of Bone and Mineral Research, Vol. 33, February 2018, pp 190–198

• In conclusion, denosumab substantially reduces the risk of vertebral fractures, and soon after treatment discontinuation, a patient’s risk of vertebral fracture returns to the level before treatment initiation.

• Additionally, more than half of patients who sustain a vertebral fracture have multiple vertebral fractures.

• Physicians should keep careful track of the dates when a patient’s next dose of denosumab is due.

I

If a patient discontinues denosumab, particularly if she has had a vertebral fracture, the patient should promptly receive a bisphosphonate or another

antiresorptive agent to prevent the increased risk of vertebral fractures, especially multiple vertebral

fractures, that develop soon after stopping denosumab.

Denosumad reduce las fracturas vertebrales a largo plazo.

PERO al parar remedio vuelve al riesgo similar al previo.

Más de la mitad casos presenta múltiples fracturas

vertebrales.

Vertebral Fractures After Discontinuation ofDenosumab: A Post Hoc Analysis of the Randomized

Placebo-Controlled FREEDOM Trial and Its Extension.

Journal of Bone and Mineral Research, Vol. 33, February 2018, pp 190–198

Múltiples fracturasvertebrales

Therefore, patients who discontinue denosumab should

rapidly transition to an alternative antiresorptive treatment

Romosozumab or Alendronate for FracturePrevention in Women with Osteoporosis.

Sept. 11, 2017, at NEJM

13 veces citado-.-.-

n=4.093 mujeres osteoporóticas con fractura vertebral PREVIARendomizado-multicéntricoRomosozumab 210mg sbc./mes - Aledronato 70mg/mensual POSeguidos por 24 meses = incidencia fracturas vertebrales y otras• ROMOSOZUMAB redujo fracturas vertebrales a los 12 y 24 meses• Redujo 19% no vertebrales y 38% de caderas


Sept. 11, 2017, at NEJM.org.

un año

Alendronato 70mg/semanal

3 años


Sept. 11, 2017, NEJM

Incidencia NUEVAS fracturas Vertebrales

12 MESES24 meses

Primera fractura NO VERTEBRAL

Benefits and Harms of Osteoporosis Medications in Patients With Chronic Kidney Disease.

A Systematic Review and Meta-analysis

Data Sources: PubMed and the Cochrane Central Register of Controlled Trials from December 2006 through December 2016.

Conclusion: Effects of osteoporosis medications on BMD, fracture risk, and safety among patients with CKD

are not clearly established.

Ann Intern Med. 2017;166:649-658.

AUN FALTAN MAS-MEJORES ESTUDIOS

Effect of Longer-Interval vs Standard Dosing of ZoledronicAcidon Skeletal Events in Patients With Bone Metastases

A Randomized Clinical Trial.

CONCLUSIONS AND RELEVANCE Among patients with bone metastases due to breast cancer,

prostate cancer, or multiple myeloma, the use of zoledronic acid every 12 weeks compared

with the standard dosing interval of every 4 weeks did not result in an increased risk of

skeletal events over 2 years.

JAMA. 2017;317(1):48-58.

A 2 años = Acido ZOLENDRONICO es idem cada 4 o 12 semanas

MEJOR usarlo MAS ESPACIADO

Effect of Longer-Interval vs Standard Dosing of ZoledronicAcidon Skeletal Events in Patients With Bone Metastases

A Randomized Clinical Trial

JAMA. 2017;317(1):48-58.

Cada 12 semanas es idem

que 4 semanas

Effects of teriparatide and risedronate on new fractures inpost-menopausal women with severe osteoporosis (VERO):

a multicentre, double-blind, double-dummy, randomisedcontrolled trial.

www.thelancet.com online November 9, 2017 http://dx.doi.org/10.1016/S0140-6736(17)32137-2

Trial “cabeza-cabeza” de dos tratamientos• 24 meses-mujeres postmenopáusicas con

fracturas vertebrales previas = Osteoporosis Severa (n=268 en cada grupo)

• End point =incidencia nuevas fracturas vertebrales por Rx.

• Mejor resultado con Teriparatide sbc. que Riserdonato 35mg/semanal.




FORTEO-R

Incidencia NUEVAS FRACTURAS vertebral




Primera fractura NO vertebral Primera fractura vertebralCLINICA




DOLOR LUMBAR

FRAX-based intervention and assessment

thresholds in seven Latin American countries.

https://doi.org/10.1007/s00198-017-4341-4

P. Clark. Denova-Gutiérrez, Zerbini. Sanchez, Messina, J. Jaller, C. Campusano, C. H. Orces G. Riera H. Johansson J. A. Kanis

Osteoporosis Internationalhttps://doi.org/10.1007/s00198-017-4341-4

IOF Compendium of OsteoporosisFirst Edition, October 2017

2017 International Osteoporosis Foundation

MUCHAS GRACIAS.

Dr. Pedro Paulo Marín Larraín

[email protected]

2017 papers internacionales. · 1. osteoporosis international = 262 2. j bone mineral research =...

Documents